ONL Therapeutics secures financing to advance lead compound into Phase 2 clinical trial
March 9th 2023According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.
Discovery suggests new way to prevent common causes of vision loss
March 6th 2023Researchers have identified a new target to prevent the formation of abnormal tangles of blood vessels associated with eye conditions such as neovascular age-related macular degeneration, proliferative diabetic retinopathy and ischemic retinal vein occlusion.
Botulinum toxin injections offer an alternative to extraocular muscle surgery for comitant esotropia
March 5th 2023According to researchers, the treatment with botulinum toxin is safe, fast-acting, and improves both cosmetic appearance and quality of life, and could be considered as a choice for patients not opting for surgery.
Study: Fovea-involving half dose of PDT proves a safe, long-term treatment option for chronic CSC
March 3rd 2023According to researchers, patients with chronic CSC treated with 1 fovea-involving, half-dose PTD application had a significant improvement in structure and function at the final follow-up and foveal atrophy did not develop in any patients.